APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
A phase 1/2 trial of Toripalimab in sarcomas, run by Ascentage Pharma Group Inc., now recruiting.
Overview
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04785196 by Ascentage Pharma Group Inc., with 95 participants planned, started 2021-05-26 and due to reach its primary completion in 2026-04. Interventions recorded: APG-115 and Toripalimab.
Similar pages
not linked directly; found by shared links- TrialStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma and the tag pipeline.
- TrialA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Ascentage Pharma and the tag pipeline.
- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- TrialSTC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Shares Toripalimab, Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab and the tag pipeline.